BP Prudhoe Bay Royalty Trust Announces No Unit Payment for the Second Quarter of 2025 and Update on NYSE Delisting
For the three months ended June 30, 2025, the Per Barrel Royalty was calculated based on the following information:
The average daily closing WTI price was below the 'break-even' price for the quarter, resulting in a negative value for the payment calculation for the quarter. However, as provided in the Trust Agreement, the payment with respect to the Royalty Interest for any calendar quarter may not be less than zero.
As previously disclosed, the Trust terminated at 11:59 PM on December 31, 2024, and The Bank of New York Mellon Trust Company, N.A., as trustee (the 'Trustee'), has commenced the process of winding up the affairs of the Trust. The Trustee cannot predict when the wind-up of the Trust will be completed.
Delisting from NYSE
The Trust also announced that on June 30, 2025, it had received notification from the New York Stock Exchange ('NYSE') of its determination to suspend trading of the Trust's units of beneficial interest (the 'Units'), effective as of the close of trading on June 30, 2025, and to initiate proceedings to delist the Units. The determination to commence the delisting proceeding results from the Trust's inability to satisfy the continued listing compliance standards set forth under Rule 802.01C of the NYSE Listed Company Manual because the average closing price of the Units fell below $1.00 over a 30 consecutive trading-day period that ended on December 30, 2024, and the Trust was unable to regain compliance with the applicable standards within a cure period that concluded on June 30, 2025.
As a result of the suspension, the Units began trading on July 1, 2025, under the symbol 'BPPTU' on the Pink Limited Market ('OTC Pink'), which is operated by OTC Markets Group, Inc. To be quoted on OTC Pink, a market maker must sponsor the security and comply with SEC Rule 15c2-11 before it can initiate a quote in a specific security. OTC Pink is a significantly more limited market than the NYSE, and the quotation of the Units on OTC Pink may result in a less liquid market available for existing and potential unitholders and could further depress the trading price of the Units. There is no assurance that an active market in the Units will develop on OTC Pink.
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release are subject to a number of risks and uncertainties beyond the control of the Trust. These forward-looking statements include the Trust's expectations regarding the timing of the transition of the quotation of the Units to OTC Pink, expectations regarding the trading of the Units on OTC Pink and the Trust asset sale process. Descriptions of some of the risks that could affect the future performance of the Trust appear in the Trust's Annual Report on Form 10-K for the year ended December 31, 2024, the Trust's subsequent Quarterly Reports on Form 10-Q, and the Trust's other filings with the Securities and Exchange Commission (the 'SEC'). The Trust's annual, quarterly and other filed reports are or will be available over the Internet at the SEC's website at http://www.sec.gov. The Trustee undertakes no obligation to update forward-looking statements after the date of this report, except as required by law, and all such forward-looking statements in this report are qualified in their entirety by the preceding cautionary statements.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Elevance Health Insiders Sold US$6.9m Of Shares Suggesting Hesitancy
Over the past year, many Elevance Health, Inc. (NYSE:ELV) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, if numerous insiders are selling, shareholders should investigate more. While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. In the last twelve months, the biggest single sale by an insider was when the Executive VP & President of Commercial Health Benefits, Charles Kendrick, sold US$3.2m worth of shares at a price of US$432 per share. That means that an insider was selling shares at around the current price of US$396. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern. Elevance Health insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below! View our latest analysis for Elevance Health If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar). Over the last three months, we've seen significant insider selling at Elevance Health. Specifically, Executive VP & CFO Mark Kaye ditched US$1.9m worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain. For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Elevance Health insiders own 0.1% of the company, currently worth about US$103m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. An insider hasn't bought Elevance Health stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of Elevance Health. But note: Elevance Health may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
19 minutes ago
- Yahoo
Graco Inc. Announces Second Quarter 2025 Earnings Conference Call
MINNEAPOLIS, July 02, 2025--(BUSINESS WIRE)--Graco Inc. (NYSE: GGG) announced today that it will release its Second Quarter 2025 earnings after the New York Stock Exchange closes on Wednesday, July 23, 2025. A full-text copy of the earnings announcement will be available on the company's website at Graco management will hold a conference call, including slides via webcast, with analysts and institutional investors to discuss the results at 11 a.m. EDT / 10 a.m. CDT on Thursday, July 24, 2025. A real-time listen-only webcast of the conference call will be broadcast on the company's website and by going here: Listeners should register on the website at least 15 minutes prior to the live conference call. For those unable to listen to the live event, a replay of the webcast will be available on the company's website at ABOUT GRACO Graco Inc. supplies technology and expertise for the management of fluids in both industrial and commercial applications. It designs, manufactures and markets systems and equipment to move, measure, control, dispense and spray fluid and powder materials. A recognized leader in its specialties, Minneapolis-based Graco serves customers around the world in the manufacturing, processing, construction and maintenance industries. For additional information about Graco Inc., please visit us at View source version on Contacts FOR FURTHER INFORMATION: Investors: David M. Lowe, 612-623-6456Media: Meredith A. Sobieck, 612-623-6427Meredith_A_Sobieck@ Sign in to access your portfolio
Business Wire
20 minutes ago
- Business Wire
CORRECTING and REPLACING SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
NEW YORK--(BUSINESS WIRE)--Third paragraph, second sentence of release should read: These include the current Board's failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac's prior public accounting firm to resign in April, and its poor governance practices. The updated release reads: SAIF PARTNERS: NOW IS YOUR LAST CHANCE TO VOTE FOR BOARD CHANGE AT SINOVAC Sinovac's Special Meeting of Shareholders is Just Days Away; Your Vote Matters No Matter How Many Shares You Own SAIF Partners Urges Shareholders to Vote the GOLD Proxy Card ' FOR ' its Director Candidates to End Years of Chaos, Restore Credibility and Unlock Long-Term Value for All Sinovac Shareholders SAIF Partners IV L.P., ('SAIF Partners', 'we' or 'us'), the largest single investor in Sinovac Biotech Ltd. ('Sinovac' or the 'Company') which beneficially owns approximately 15% of the Company's outstanding common shares, today urged shareholders to immediately vote ' FOR ' the election of SAIF Partners' ten highly qualified director candidates to the Company's Board of Directors (the 'Board') using the GOLD proxy card. Sinovac's Special Meeting of Shareholders (the 'Special Meeting') – scheduled for Tuesday, July 8 at 8:00 p.m. Atlantic Standard Time (Wednesday, July 9 at 8:00 a.m. China Standard Time) – is just days away, and time is running out to cast your vote for change. SAIF Partners firmly believes that Sinovac's current Board – the majority of whose members were not duly elected by shareholders or sanctioned by the Privy Council – does not act in the interests of all shareholders, and in fact only began to do so when it was publicly pressured. Further, we believe the current Board lacks integrity, industry experience, management expertise, and respect for the law necessary to fulfill its lofty promises to shareholders. As such, we do not believe the current Board has the capability to resolve the Company's most pressing issues, including concluding its numerous lawsuits and ending the six-year suspension of the trading of Sinovac's common shares in the public markets. Most importantly, however, we are highly skeptical of the current Board's ability to follow through on its plan to issue significant dividends to shareholders for several concerning reasons. These include the current Board's failure to actively engage with management, its lack of sound financial reasoning for its proposed dividend figures, its apparent unwillingness to hire a new independent auditor after it drove Sinovac's prior public accounting firm to resign in April, and its poor governance practices. These issues, among others, lead us to believe that the current Board has put forth its massive dividend distribution plan simply to win shareholders' support and retain their positions, even though it lacks the capabilities to follow through on its stated promise. Ultimately, we believe that meaningful change is urgently needed on Sinovac's Board to restore the Company's credibility with investors and regulators and unlock the tremendous long-term value embedded within Sinovac for all shareholders. If elected, our nominees will work closely with management to deliver shareholders the long-overdue dividends they deserve and establish a long-term business strategy that will maximize the value of the Company for all shareholders. Now is Your Chance to Elect a Board that Will Act in the Best Interest of ALL Sinovac Shareholders Vote the GOLD Proxy Card Today 'FOR' Proposal 1 and Proposal 2 to Remove Sinovac's Current Board and Elect SAIF Partners' Highly Qualified Director Candidates VISIT TO CAST YOUR VOTE USING YOUR UNIQUE CONTROL NUMBER LOCATED ON YOUR GOLD PROXY CARD. IF YOU RECEIVED A GOLD PROXY CARD BY EMAIL, CLICK THE LINK IN YOUR EMAIL TO CAST YOUR VOTE IF YOU DID NOT RECEIVE A GOLD PROXY CARD OR IF YOU HAVE LOST YOUR GOLD PROXY CARD, CHECK YOUR SPAM FOLDER OR CONTACT YOUR BROKER TO ASK FOR YOUR CONTROL NUMBER. IF YOU HAVE ALREADY VOTED USING THE COMPANY'S WHITE PROXY CARD, YOU CAN STILL CHANGE YOUR VOTE BY USING YOUR GOLD PROXY CARD. About SAIF Partners SAIF Partners is a leading Asian private equity firm with cumulative assets under management of over $4 billion. SAIF Partners is an active lead investor working closely with its portfolio companies to develop their business both organically and through acquisitions, seeking synergistic cooperation among them, as well as enhancing shareholder value via promotion of good corporate governance and best management practices. Additional Information and Where to Find It This communication may be deemed to be solicitation material in respect of SAIF Partners' nomination of ten director nominees to Sinovac's Board. In connection with such solicitation, SAIF Partners mailed the definitive proxy statement and proxy card to shareholders of Sinovac with respect to the Special Meeting to be held in connection with the election of directors to Sinovac's Board. The definitive proxy statement mailed by SAIF Partners is also filed as Exhibit 1 to its Schedule 13D/A filed on or about June 16, 2025. SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH SINOVAC'S SPECIAL MEETING, INCLUDING ANY DOCUMENT INCORPORATED BY REFERENCE THEREIN, CAREFULLY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE DIRECTOR NOMINEES AND THE SPECIAL MEETING AND RELATED MATTERS. Sinovac's shareholders may obtain, free of charge, the definitive version of the proxy statement, any amendments or supplements thereto, and any other relevant documents mailed by SAIF Partners in connection with the Special Meeting at
